Results 201 to 210 of about 22,351 (243)

Clinical Pharmacokinetics of Fingolimod

Clinical Pharmacokinetics, 2012
Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compounds and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).
Olivier J David, Robert L Schmouder
exaly   +2 more sources

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

Journal of Neurology, 2022
The majority of multiple sclerosis [MS] patients treated with fingolimod fail to develop a protective level of IgG humoral and adaptive cellular immune responses following full BNT162b2 SARS-CoV-2 vaccination.
Anat Achiron, Mathilda Mandel, Michael Gurevich   +2 more
exaly   +2 more sources

Delayed fingolimod-associated asystole

Multiple Sclerosis Journal, 2011
Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS).
Joseph R Berger
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.

Schizophrenia Research, 2023
OBJECTIVES Studies have suggested that fingolimod, a sphingosine-1-phosphate receptor modulator, exerts neuroprotective and anti-inflammatory effects. Although fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis, limited ...
Monire Karbalaee, Melika Jameie, Mobina Amanollahi, Fateme Taghavizanjani, Mohammadamin Parsaei, Fatemeh A. Basti, Saba Mokhtari, Kamyar Moradi, M. K. Ardakani, S. Akhondzadeh   +9 more
semanticscholar   +1 more source

Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.

Journal of Hepatology, 2023
BACKGROUND Hepatopulmonary syndrome (HPS) is characterized by a defect in arterial oxygenation induced by pulmonary vascular dilatation in liver disease patients.
S. Baweja, Anupama Kumari, Preeti Negi, Arvind Singh Tomar, D. Tripathi, A. K. Mourya, Aayushi Rastogi, P. Subudhi, Swati Thangariyal, G. Kumar, J. Kumar, G. Reddy, A. Sood, Chitranshu Vashistha, Vivek Sarohi, C. Bihari, R. Maiwall, S. Sarin   +17 more
semanticscholar   +1 more source

Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.

Multiple Sclerosis and Related Disorders, 2023
INTRODUCTION Fingolimod is a disease-modifying therapy for multiple sclerosis (MS) that modulates sphingosine 1-phospate receptors, impeding the egress of lymphocytes from lymphnodes and thus causing lymphopenia.
D. Caliendo, Maria Carmela Grassia, A. Carotenuto, M. Petracca, R. Lanzillo, V. Brescia Morra, M. Moccia   +6 more
semanticscholar   +1 more source

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Journal of Neurology Neurosurgery & Psychiatry, 2022
Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod.
Chao Zhu, Zhen Zhou, I. Roos, Daniele Merlo, T. Kalincik, S. Ozakbas, O. Skibina, J. Kuhle, S. Hodgkinson, C. Boz, R. Alroughani, J. Lechner-Scott, M. Barnett, G. Izquierdo, A. Prat, D. Horáková, E. Kubala Havrdová, R. Macdonell, F. Patti, S. Khoury, M. Slee, R. Karabudak, M. Onofrj, V. van Pesch, J. Prevost, M. Monif, V. Jokubaitis, A. van der Walt, H. Butzkueven   +28 more
semanticscholar   +1 more source